Skandinaviska Enskilda Banken (SEB)’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $261K | Sell |
1,870
-2,115,680
| -100% | -$296M | 0.01% | 144 |
|
|
2025
Q4 | $260M | Sell |
2,117,550
-163,190
| -7% | -$19.8M | 1.04% | 14 |
|
|
2025
Q3 | $253M | Sell |
2,280,740
-72,218
| -3% | -$8.21M | 1.02% | 14 |
|
|
2025
Q2 | $261M | Buy |
2,352,958
+252,108
| +12% | +$26.8M | 1.14% | 12 |
|
|
2025
Q1 | $235M | Buy |
2,100,850
+282,970
| +16% | +$29.2M | 1.16% | 14 |
|
|
2024
Q4 | $167M | Buy |
1,817,880
+1,085,987
| +148% | +$97.8M | 0.76% | 25 |
|
|
2024
Q3 | $61.3M | Buy |
731,893
+146,309
| +25% | +$11.2M | 0.28% | 62 |
|
|
2024
Q2 | $40.2M | Sell |
585,584
-512,849
| -47% | -$34.2M | 0.19% | 90 |
|
|
2024
Q1 | $80.4M | Sell |
1,098,433
-531,450
| -33% | -$40.9M | 0.39% | 45 |
|
|
2023
Q4 | $132M | Sell |
1,629,883
-76,458
| -4% | -$5.95M | 0.76% | 23 |
|
|
2023
Q3 | $128M | Buy |
1,706,341
+96,281
| +6% | +$7.41M | 0.84% | 19 |
|
|
2023
Q2 | $124M | Sell |
1,610,060
-60,485
| -4% | -$4.82M | 0.81% | 21 |
|
|
2023
Q1 | $139M | Buy |
1,670,545
+74,764
| +5% | +$6.19M | 0.97% | 18 |
|
|
2022
Q4 | $137M | Buy |
1,595,781
+86,629
| +6% | +$6.86M | 1.03% | 11 |
|
|
2022
Q3 | $93.1M | Sell |
1,509,152
-77,169
| -5% | -$4.87M | 0.72% | 24 |
|
|
2022
Q2 | $98M | Buy |
1,586,321
+106,913
| +7% | +$6.62M | 0.72% | 21 |
|
|
2022
Q1 | $88M | Sell |
1,479,408
-666,453
| -31% | -$42.6M | 0.52% | 38 |
|
|
2021
Q4 | $157M | Buy |
2,145,861
+248,016
| +13% | +$17.1M | 0.81% | 20 |
|
|
2021
Q3 | $133M | Buy |
1,897,845
+175,606
| +10% | +$12.3M | 0.73% | 23 |
|
|
2021
Q2 | $119M | Sell |
1,722,239
-133,110
| -7% | -$8.89M | 0.73% | 20 |
|
|
2021
Q1 | $120M | Buy |
1,855,349
+290,525
| +19% | +$18.7M | 0.79% | 21 |
|
|
2020
Q4 | $91.2M | Sell |
1,564,824
-233,205
| -13% | -$14.1M | 0.63% | 24 |
|
|
2020
Q3 | $114M | Buy |
1,798,029
+69,336
| +4% | +$4.81M | 0.83% | 17 |
|
|
2020
Q2 | $133M | Sell |
1,728,693
-262,288
| -13% | -$20.1M | 1.08% | 16 |
|
|
2020
Q1 | $149M | Sell |
1,990,981
-1,143,699
| -36% | -$79M | 1.51% | 11 |
|
|
2019
Q4 | $204M | Sell |
3,134,680
-191,790
| -6% | -$12.5M | 1.6% | 9 |
|
|
2019
Q3 | $211M | Sell |
3,326,470
-1,335,120
| -29% | -$87.3M | 1.78% | 4 |
|
|
2019
Q2 | $315M | Buy |
4,661,590
+370,724
| +9% | +$24.4M | 2.72% | 1 |
|
|
2019
Q1 | $279M | Sell |
4,290,866
-560,341
| -12% | -$37.2M | 2.55% | 2 |
|
|
2018
Q4 | $303M | Buy |
4,851,207
+853,183
| +21% | +$59.6M | 2.72% | 3 |
|
|
2018
Q3 | $309M | Buy |
3,998,024
+2,959,697
| +285% | +$224M | 2.35% | 5 |
|
|
2018
Q2 | $73.6M | Buy |
1,038,327
+96,065
| +10% | +$6.78M | 0.63% | 41 |
|
|
2018
Q1 | $71M | Sell |
942,262
-3,634,807
| -79% | -$289M | 0.68% | 37 |
|
|
2017
Q4 | $328M | Sell |
4,577,069
-350,516
| -7% | -$26.6M | 2.82% | 3 |
|
|
2017
Q3 | $399M | Buy |
4,927,585
+3,434,450
| +230% | +$263M | 3.62% | 2 |
|
|
2017
Q2 | $106M | Sell |
1,493,135
-29,743
| -2% | -$1.98M | 1.02% | 19 |
|
|
2017
Q1 | $103M | Sell |
1,522,878
-51,317
| -3% | -$3.61M | 1.04% | 20 |
|
|
2016
Q4 | $113M | Sell |
1,574,195
-125,140
| -7% | -$9.3M | 1.35% | 20 |
|
|
2016
Q3 | $134M | Sell |
1,699,335
-646,025
| -28% | -$52.5M | 1.45% | 16 |
|
|
2016
Q2 | $196M | Sell |
2,345,360
-48,500
| -2% | -$4.3M | 2.19% | 7 |
|
|
2016
Q1 | $220M | Sell |
2,393,860
-126,600
| -5% | -$11.4M | 2.47% | 4 |
|
|
2015
Q4 | $257M | Buy |
+2,520,460
| New | +$262M | 3.34% | 2 |
|
Other funds holding GILD
VCM
VPM
Skandinaviska Enskilda Banken (SEB)'s GILD Position: Q1 2026 in Review
Skandinaviska Enskilda Banken (SEB) reduced its Gilead Sciences (GILD) stake by 100% in Q1 2026, selling an estimated $296M and leaving 1,870 shares worth $261K. The position accounts for 0.01% of the portfolio, ranked #144.
Skandinaviska Enskilda Banken (SEB) first reported a position in GILD in Q4 2015 and has held it in 42 quarters since. The position peaked at $399M in Q3 2017. 2,315 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Skandinaviska Enskilda Banken (SEB) held 1,870 shares of Gilead Sciences worth $261K as of Q1 2026.
- Skandinaviska Enskilda Banken (SEB) sold 2,115,680 Gilead Sciences shares in Q1 2026, an estimated $296M.
- Gilead Sciences made up 0.01% of Skandinaviska Enskilda Banken (SEB)'s portfolio in Q1 2026, its #144 holding.
- Skandinaviska Enskilda Banken (SEB) first reported a position in Gilead Sciences in Q4 2015 and has held it in 42 quarters since.
- Skandinaviska Enskilda Banken (SEB)'s Gilead Sciences position peaked at $399M in Q3 2017.
- 2,315 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q1 2026, filed 15 May 2026.